Research efforts, focused on finding additional, more precise biomarkers that would better predict response to ICIs in addition to MSI/PD-1/PD-L1 status, have culminated in several new findings, such as the analysis of mutational burden in plasma-circulating tumour DNA (ctDNA), immune prognostic signatures, evaluation of the composition and ratios of immune cell subtypes, and so on [16,65,71,109,110,111]. The gene discussed is CD274; the disease is neoplasm.